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Abstract. Currently a growing interest to improve the 
pharmacological therapy exists, not only by the production and the 
appearance of new drugs, but guaranteeing that the uses of those 
which already exist, become more effective. In fact, the 
conventional pharmaceutical formulations of different drugs present 
a few secondary effects due to oral administration. In order to avoid 
these undesired side effects, the purpose of current therapeutic is  
the development and research of formulations as an alternative              
to others routes of administration. Therefore, in spite of the 
undoubtedly complete parenteral absorption, the transdermal               
and transbuccal routes appear to be a rather attractive alternative          
to provide an efficient absorption. In this chapter a new 
technological, biopharmaceutical and pharmacokinetic approach of                     
strategies for application on skin and buccal mucosa are reported.  
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In the future new transdermal drug delivery systems will emerge to be more effective, 
equipped with an improved aesthetic appearance, better adherence and greater 
diffusion. But to reach these aims, it is necessary previous knowledge of histology and 




 The pharmaceutical sciences are faced with a need to develop alternative 
dosage forms for transdermal and transmucosal absorption. In addition to oral 
and parenteral routes, the suitable sites for administering drugs are the nasal, 
vaginal, rectal or ocular mucosa. However the oral mucosa represents the 
most popular route, because of its excellent permeability, good accessibility, 
high patient acceptance and compliance, the dosage forms can be easily 
attached to and removed from the mucosa. Moreover oral mucosa is routinely 
exposed to different compounds and therefore is supposed to be rather robust 
and less prone to irreversible irritation or damage by the drug, the dosage 
form, absorption promoters, etc. In fact, the turnover time for the buccal 
epithelium has been estimated at 5–6 days [1]. 
 Within the oral mucosal cavity, the buccal region offers an attractive route 
of administration over peroral administration; buccal routes offer the 
advantages of avoiding hepatic first-pass metabolism, local intestinal enzymes 
and secretions and are deficient in enzymatic degradation. 
 In the other hand, the transdermal administration of drugs offers 
advantages that can enhance the therapeutic benefits of the active substances. 
This route of administration avoids the gastrointestinal tract and 
biotransformation due to the first-pass effect and metabolism in the liver. 
Drug release is targeted at the specific site where it is needed, and the 
percentage of absorption can be controlled. Delayed release formulations can 
be used. Systemic secondary effects are reduced, and topical formulations are 
easy to apply, a factor that improves patient compliance. Substantial 
concentrations of the drug can be reached in the soft tissues at the site of 
application. In addition, transdermal formulations can be used in readily 
accessible sites, and such formulations are nontoxic and easy to use. 
 These advantages, in both routes, are particularly useful with drugs that 
can break down in the gastrointestinal tract, or drugs used for long-term 
treatments, intravenously, or for osteoarticular wounds.  
 
1. Anatomy, physiology and permeability of the oral mucosa and skin 
 
 Despite the advantages of transdermal and transbuccal pathways, the 
primary function of skin and oral mucosa is the protection of the underlying 
tissue. Therefore, to set the stage for subsequent discussion of strategies for 
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use of dosage forms in transdermal and transmucosal drug delivery, basic 
physiological characteristic of the skin and oral mucosa should be mentioned. 
 
1.1. Oral mucosa 
 
 Drugs can be absorbed from any of the mucosal tissues in the oral cavity: 
maxillary artery supplies blood to buccal mucosa and blood flow is faster and 
richer (2.4 mL/min/cm2) than that in the sublingual (beneath the tongue), 
gingival and palatal regions, thus facilitates passive diffusion of drug molecules 
across the mucosa.  
 Buccal mucosa is composed of several layers of different cells, but 
consists principally of two components, an epithelium and an underlying 
connective tissue (basal lamina, propria lamina and submucosa). Also 
numerous racemose, mucous, serous glands and major blood vessels and 
nerves are present in the submucous tissue of the cheeks [2]. The epithelium 
of the human oral mucosa shows two distinct patterns of maturation, non-
keratinized and keratinized. The most interesting, non-keratinized epithelium 
forms the surface of the distensible lining of the soft palate, ventral surface of 
the tongue, floor of the mouth, alveolar mucosa, vestibule, lips, and cheek.    
 The epithelium and its basal lamina constitute the major resistance barrier 
[3]. Substances can cross the buccal epithelial membrane by the mechanisms 
of simple diffusion, carrier-mediated diffusion (intercellular or intracellular), 
active transport, and endocytosis [4]. Most permeability studies (large 
molecules) point towards intercellular via [5].   
 The flux of drug through the membrane under sink condition for 




 Where, Dp is the diffusion coefficient of the permeate in the intercellular 
spaces, hp is the path length of the paracellular route, ε is the area fraction of 
the paracellular route and Cd is the donor drug concentration. 
 Similarly, flux of drug through the membrane under sink condition for 




Where, Kc is the partition coefficient between lipophilic cell membrane and 
the aqueous phase, Dc is the diffusion coefficient of the drug in the 
transcellular spaces and hc is the path length of the transcellular route [6].  
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 In general, lipophilic drugs are absorbed through the intracellular route, 
whereas hydrophilic drugs are absorbed through the intercellular route, but the 
rate of penetration varies depending on the physicochemical properties of the 
molecule and the type of tissue being traversed. This has led to the suggestion 
that materials use one or more of the following routes simultaneously to cross 
the barrier region in the process of absorption, but one route is predominant over 
the other depending on the physicochemical properties of the diffusant [7]. So, 
the absorption potential of the buccal mucosa is influenced by the lipid 
solubility, molecular weight of the diffusant and carrier pH [8]. In addition, the 
microenvironment of the buccal cavity lends itself to modifications, in very few 
cases also the barriers such as saliva, mucus, membrane coating granules, retard 
the rate and extent of drug absorption through the buccal mucosa. All affects its 
bioavailability, hence development of unidirectional release systems with 




 The functions of the skin are thermoregulatory, immunological, mediation 
of sensation, social and protective. Barrier function plays the most important 
role in drug development and pharmacokinetic implications for both topically 
and systemically administered drugs. However the skin is the most accessible 
organ of the body but it is designed to isolate the organism from the external 
milieu, and thus poses a challenge to the pharmaceutical development of 
excipients that yield optimal permeation and cutaneous absorption of the 
active principles. 
 The skin is a complex organ consisting of three anatomical layers, the 
epidermis, the dermis and a subcutaneous fat layer. Moreover, the skin is 
pierced by the sebaceous and eccrine sweat glands and the hair follicles [10].  
 The epidermis is in humans 0.02-0.2 mm thin. The epidermis is made up 
of two layers: the stratum germinativum and the stratum corneum.  The 
stratum corneum is a dead fully keratinised cells tissue. The functions are: 
protective, against external environment, occlusive, preventing body water 
loss (dehydration), and receptor for epidermal metabolic products. In fact, the 
stratum corneum provides the major barrier to penetration of topically applied 
drugs due to its lipid-rich nature and its low water content. The water content 
of the normal stratum corneum is 20-30%. The intracellular lipids consist of 
ceramides, fatty acids and cholesterol. There are also other intracellular lipids 
or lipids from the sebaceous glands or from epidermal fat [11]. 
 The region below epidermis is called dermis. It supports and strengthens 
the epidermis. It ranges 5–20-times thicker than epidermis (approximately    
2-3 mm thick). The dermis contains fibrous protein collagen, elastin, 
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histiocytes, mastocytes, water, ions, carbohydrates, blood and lymphatic 
vessels and nerves. The dermis is therefore a sensitive and highly irrigated 
tissue. Through the blood vessels in the dermis, the drugs enter the circulation 
system; firstly they have to cross the stratum corneum.  
 The subcutaneous fat layer or hipodermis represents the separation zone 
between the dermis and underlying tissues. It is composed of fat and elastic 
fibers. The hypodermis is the base of hair follicles and the sweat glands. It is 
also a well irrigated and innervated layer. Sometimes, the fat deposits may serve 
as a deep compartment for the drug and this can delay entry into the blood. 
 Number and type of hair follicles and glands is very relevant for drug 
penetration. In this zone of appendices, the stratum corneum thickness 
decreases, and even may disappear. Consequently the appendices are 
important access roads. The number of appendices varies depending on the 
species and anatomical region [12].  
 
2. Cutaneous and transbuccal metabolism 
 
 Drug absorbed through the oral mucosa enters the systemic circulation 
directly via the jugular vein, avoiding the liver where they might be 
metabolized. However the drugs which are swallowed in the saliva do not 
avoid first pass metabolism and will be subjected to degradation by digestive 
juices. This may be partly overcome by using a drug delivery system which 
has a unidirectional drug outflow [13, 14].  
 Also, the enzymatic activity on the surface of the buccal mucosa should 
be evaluated as a barrier to drugs buccal delivery. In this way, the inclusion of 
enzyme inhibitors in buccal bioadhesive delivery systems could improve 
buccal bioavailability [15].  
 The viable part of the epidermis represents an enzymatic barrier for drugs 
after topical application. The distribution of the enzyme system will depend 
on the anatomical area and the species [16, 17], causing some differences in 
absorption and considerable transdermal first pass metabolism [18-20]. 
 In vivo enzymatic activity in the epithelium can activate pro-drugs 
decreasing the delivery [21]. 
 The stratum corneum can act as a reservoir for drugs, causing the 
pharmacological response to continue for a short time after the device has 
been removed. In other cases, depending on the delivery system, the drug will 
diffuse into underlying layers. The results presented indicate that most of the 
enzyme activity of the skin may be localized in the epidermal layer.  
 For this reason, the study of skin metabolism should take into account not 
only in the field of transdermal drug delivery but also for the safe and efficient 
local skin treatment with topically applied substances. 
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 Finally, the oral mucosa contains the greatest variety of micro-organisms, 
which could alter drugs [22]. The entry into the body of these organisms is 
limited by the oral epithelium, which is not, as is often suggested, a highly 
permeable membrane. 
 Skin surface contains many and some potentially pathogenic microbiota. 
The drugs topically applied can be metabolised by bacteria on the skin surface 
[23]. Also, this bacterial population can encourage its growth due to heat or 
humidity transdermal system. It must be kept in mind when opening pores in 
skin and oral barrier. 
 Despite these disadvantages, the enzymes in the skin are essential in order 
to maintain skin good conditions contribute to the right skin pH and maintain 
skin protective capability against pathogens or reactive oxygen species. 
 Finally, it must be emphasized that the delivery system properties (e.g. 
permeation enhancers) and regional variations  might  be considered as a 
potential reason for inter- and intra-individual variations in metabolism and 
bioavailability of transdermally administered drugs [24, 25].  
 
3. Pharmaceutical considerations 
 
 To a certain extent, the structure of the oral mucosa resembles that of the 
skin. For this reason some pharmaceutical considerations are general. Great care 
needs to be exercised while developing a safe and effective buccal adhesive 
drug delivery device. Factors influencing drug release and penetration through 
buccal mucosa, organoleptic factors, and effects of additives used to improve 
drug release pattern and absorption, the effects of local drug irritation caused at 
the site of application or texture of buccal mucosa, thickness of the mucus layer, 
its turn over time and effect of saliva are to be considered while designing a 
formulation. Also, the buccal epithelium is a lipoidal barrier, hence the majority 
of absorption of drugs is passive. However, some authors have demonstrated an 
active transport [26-28].    
 Another very important factor is the location of drug release system. The 
dosage form may be used as sublingual, buccal, local or periodontal delivery 
system. Variations in oral physiology will undoubtedly affect drug absorption.  
 In the other hand, the permeation of topically applied drugs into the 
systemic circulation consists of three phases:  
 
- The release from the vehicle: the drug may be dissolved in the excipient 
and then diffuse to contact the skin surface. 
- In a transdermal device, the primary design goal is the maintenance of the 
desired constant drug concentration at the skin surface for a suitable 
length of time. 
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- Penetration into the epidermis and permeabilization: Once the drug 
reaches  the  vehicle/skin surface interphase, it can penetrate through the 
sweat duct, hair follicles and sebaceous glands, being dissolved in sebum 
secretion (collectively called the shunt or transappendageal via)  or 
directly across the stratum corneum (transepidermal via). 
- The passage through the dermis and the entry into the systemic 
microcirculation. 
\ 
There are several routes by which drugs can pass through the skin: 
 
- The intercellular route, the passage of drug through the lipid matrix 
between corneocytes in the stratum corneum. 
- The transcellular route, this occurs when drug passes through both the 
corneocytes and the lipid matrix within the stratum corneum. 
- The appendageal route, the passage of drug through the appendages, such 
as hair follicles and sweat glands; therefore bypassing absorption through 
the stratum corneum. 
 
 The intercellular and transcellular route are also known as 
“transepidermal via”. It has been suggested that transappendageal via is more 
rapid that transepidermal via but it is considered unimportant. Transepidermal 
via is the most important pathway of passage, especially the intercellular 
route, but all this is depending on the molecules physicochemical properties. 
 Drug penetration through the skin depends on many factors, dependent on 
animal, drugs and formulation, which can modify the efficacy of a treatment. 
 The diffusion of drug across the stratum corneum is driven by a 
thermodynamic gradient and is not determined solely by a concentration gradient. 
According to Higuchi [29], drug permeation can be represented in a mathematical 
model for the purpose of predicting dermal absorption in this equation: 
 
                                               dQ/dt= P. D. S. C/h 
 
 Where S corresponds to the total surface of application, h is the average 
thickness of the skin in this surface, D corresponds to the diffusion coefficient 
of a given drug across the skin, C is the applied drug concentration, and P the 
partition coefficient between the stratum corneum and the vehicle. From this 
equation it could be deduced the main factors affecting the rate of penetration: 
 
3.1. Drug criteria 
 
- Lipid/water partition coefficient. It is the most important factor of 
penetration in the stratum corneum, due to the lipid-rich nature of the 
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stratum corneum. Absorption of hydrophilic compounds is limited by the 
lipophilicity of the stratum corneum. However the dermis is much more 
hydrophilic than the stratum corneum and so act as a barrier to extremely 
hydrophobic compounds [30], once a hydrophilic compound has 
penetrated through this, it will partition readily into the epidermis and into 
systemic circulation [31]. So transdermal administration is ideal for 
substances with intermediate polarity.   
- Molecular weight. This factor also impacts upon drug diffusion through  
the stratum corneum and dermis. Small molecules are more likely to cross 
skin. It is defined by its diffusion coefficient D, which is inversely 
proportional to the cube root of molecular weight. The larger the 
molecular weight, the lower the diffusion coefficient. However the 
lipophilic nature of the drug seems to play the most important role in this 
fact. 
- Drug concentration. It is directly proportional to the penetration rate, 
although drug solubility in the vehicle, should not be exceeded. 
- Degree of drug dissociation. It is depending not only on skin pH, but also 
on formulation pH. 
  
 Transdermal administration has several advantages, especially in those 
drugs with a low water solubility and low bioavailability, and/or those with 
a great first pass metabolism in comparison with the oral administration. 
Moreover, pre-systemic metabolism is avoided, permitting lower daily 
doses. Blood levels of the drug can be kept for extended periods of time 
prolonging drug action and reducing the dosing frequency. Inter and intra 
patient variability is reduced, and patient compliance and acceptability 
improved. Lastly, input of drug can be stopped by removal of the patch [32].  
 
3.2. Vehicle criteria 
 
 The vehicle in which a drug is applied to the skin must be not only a 
support, but a delivery system that drives the drug to an appropriate area or 
biophase with an optimal rate of release.  The absorption of a compound into 
the skin may be impeded if it is more soluble in the vehicle it is applied in 
than the stratum corneum [33]. Then it must exit an equilibrium between 
drug-vehicle and drug-skin affinity in order to ensure the maximal 
thermodynamic activity, and this is possible when the drug contained in the 
vehicle chamber is saturated. A lipophilic drug dissolved in an aqueous 
vehicle would be absorbed before than at the same concentration from a 
vehicle with other lipophilic solvent. 
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 The vehicle is intended to function as a reservoir to provide a steady 
supply of drug and prolonging the effect. Therefore, it is important to take into 
consideration the vehicle effect will have on the dermal absorption drugs. 
 For a satisfactory release of drug from the vehicle, several conditions 
must be taken into account: 
 
- Diffusion coefficient of drug in the vehicle must be optimal, for it drug must 
be solubilized, without possessing a selective affinity toward the vehicle.  
- The lower the viscosity the greater the diffusion coefficient. 
- Vehicle must improve the permeability by hydration, occlusion or direct 
penetration. 
- Vehicle must not cause irritancy in the skin. 
 
 Optimization by a suitable formulation is responsible of residence time, 
local concentration of the drug in the mucosa and the amount of drug 
transported across the mucosa into the blood. The products for the buccal cavity 
must have good patient compliance, an ideal bioadhesive drug delivery system, 
should be easy to apply to the mucus and withstand salivation, tongue 
movement, and swallowing for a period of time. Buccal adhesive drug delivery 
systems with the size 1–3 cm2 and a daily dose of 25 mg or less are preferable. 
The maximal duration of buccal delivery is approximately 4–6 h [34]. 
 From a dermal point of view, the aim of skin applied formulations is to 
reach the skin surface, stratum corneum, viable epidermis, dermis, hair 
follicles, sweat glands or systemic circulation. Depending on the particular 
aim, the most appropriate biopharmaceutical and physicochemical aspects 
must be taken into account. 
 
3.3. Others factors   
 
 Penetration of the substances into the skin can be modified by some factors 
as age, gender, location of the skin, skin damage or disease,  as well as the well 
know regional variation in skin permeability to different molecules [35]. 
 Also, tissue vascularity determines the rate of absorption. In man, dermal 
blood flow is about 2.5 mL min-1 100 g-1.  
 Areas of the body where the stratum corneum is thickest, such as the 
palms of the hands (400 μm) and soles of the feet (600 μm) will be far less 
permeable to xenobiotic compounds than an area of the body where the 
stratum corneum is much thinner, such as the scrotum (5 μm) [36].  
 However several pharmacokinetic studies show bioequivalence of several 
anatomical sites after patch application: clonidine patch provides similar 
plasma concentration profile after application on arm and chest [37]. The rate 
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and extent of nicotine absorption from Nicoderm® were similar after 
application on upper outer arm, upper back and upper chest [38]. Plasma 
concentrations of norelgestromin and ethinyl estradiol from the contraceptive 
patch remain within the reference ranges throughout the wear period 
regardless of the application site [39].  
 Both, temperature and occlusion, increase passive diffusion [40]. 
 Equally, in older people the stratum corneum thickens and becomes less 
hydrated, decreasing absorption [41].  
 Recent studies demonstrate that skin properties in the stratum corneum 
vary considerably among ethnic groups [42]. 
 However, the main factors to consider are two: damage/disease of skin and 
its hydration. The skin sustains damage [43] or diseases [44, 45] can reduce 
barrier action and lead to increased permeability of the drugs. These processes 
are an important obstacle to the selection of the formulation.  The degree of 
hydration of the skin improved contact and hydration of the lipid channels of the 
stratum corneum. When the skin is hydrated it reduces the evaporation of 
moisture from underlying tissues, so it is better to use emollients and occlusive 
substances that moisturizers. As a result, transdermal absorption increases. 
 
4. Strategies for transdermal and transbuccal drug delivery 
systems: Current technologies of chemically and physically 
enhanced diffusive delivery 
 
 The objective of a transdermal and transbuccal delivery system is to 
provide a sustained concentration of drug for absorption avoiding local 
irritation. However the slow transport of many drugs across skin limits these 
administrations.  
 The administration of active principles on the skin and buccal mucosa 
with the aim of achieving a systemic and reservoir effect has led to 
pharmaceutical development of a new form of dosage. There are some 
methods by which penetration of compounds through the oral mucosa and 
skin can be improved: by the use of prodrug, co-administration of enzyme 
inhibitors, delivery systems, enhancers or physical methods. But particular 
caution should be taken with the creation of pores in the skin, as this has a 
large number and variety of microbiota, including pathogens. 
 
4.1. Drug delivery system in buccal mucosa 
 
 Sublingual drug delivery is more commonly used to treat acute disorders, 
whereas the buccal route is chosen when a prolonged release of drug is needed 
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in chronic disorders [46]. However bioavailabilities of some drugs by the 
buccal route were still low due to its anatomical, physiological and 
tecnological factors such as texture of buccal mucosa, thickness of the mucus 
layer, its turnover time, effect of saliva, enzymatic barrier. These factors are to 
be considered in designing the dosage forms. 
 For example, one to two litres of fluid are excreted daily into the human 
mouth and there is a continuous, low basal secretion of 0.5 mL min-1 which 
will rapidly increase to more than 7 mL min-1 by the thought, smell or taste of 
food [47]. Therefore their contact with the oral mucosa is brief. In order to 
locally treat the mucosa, delivery systems have been designed to prolong 
residence in this area. These formulations include semisolid, mucoadhesive 
patches and bioadhesive tablets. 
 The use of adhesive polymers plays an important role in the development 
of mucoadhesive dosage forms, prolonging residence on the oral mucosa, 
improving absorption, targeting of specific tissues and allow for some degree 
of sustained release of the active principle [48]. Also some bioadhesive 
polymers, such as poly(acrylic acid), polycarbophil, and carbopol, can also 
inhibit certain proteolytic enzymes (trypsin, α-chymotrypsin, 
carboxypeptidases A and B, and leucine aminopeptidase) [49]. 
 The polymers must have the following characteristics: 
 Polymer and its degradation products should be non-toxic, non-irritant, 
free from leachable impurities and easily available. Also they should have 
good spreadability, wetting, swelling and solubility, biodegradability, 
bioadhesive and viscoelastic properties, and should  demonstrate local enzyme 
inhibition and penetration enhancement properties.  
 In general, buccal dosage forms can be categorized into unidirectional or 
multidirectional and reservoir or matrix type. They also must possess the 
requirements described above. If necessary, the drug may be formulated in 
certain physical states, such as microparticles  [50], sponges  [51], liposomes  
[52, 53] or nanoparticles  [54, 55], prior to formulation of dosage form in 
order to achieve some desirable properties, e.g. enhanced activity and 
prolonged drug release. 
 Sprays and fast dissolving tablets are the two most widely used 
formulations for sublingual delivery. Tablets have been the most commonly 
investigated dosage form for buccal drug delivery to date, however they have 
a poor patient compliance.  
 Others dosage forms, such as buccal films and patches offer advantages 
due its flexibility and comfort [56]. Different drugs have been successfully 
studied obtaining optimal permeation values for a systemic effect [57, 58].  
 Certain bioadhesive polymers, e.g. pluronics show a phase change from a 
liquid to a semisolid with the corporal temperature. They have the advantage 
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of easy dispersion throughout the oral mucosa, rich retention at the site of 
application and adequate drug penetration [59].  
 In contrast to polymers utilized until now, a new generation of polymers 
can adhere directly to the cell surface, rather than to mucus [60].  
 
4.2. Drug delivery system in skin 
 
 Currently the advances on transdermal delivery systems can be divided 
into three categories; physical methods, chemical methods and other complex 
systems. These last may include vesicles, eutectic mixtures, pro-drug, 
micelles, cyclodextrins microemulsions, nanoemulsions, cubic phases, 
colloids and synergistic mixtures.  
 It also noted the success in the permeation after the combination of 
several techniques such as chemical enhancers, physical enhancers and 
vesicles [61-63]. 
 
4.2.1. Other complex systems 
 
4.2.1.1. Dosage forms (solid, liquid, semisolid)  
 
 Classical ointments, creams, lotions and gels are not suitable for action 
and/or controlled transdermal delivery.  
 When an active principle is administered topically, including in a 
conventional pharmaceutical way (solution, emulsion, gel…) through the skin, 
the latter has to release the active principle it contains so that it previously 
dissolves, is absorbed and reaches its area of activity, which in this case must 
be centred on the coetaneous tissue. Nevertheless, the arrival of the active 
principle at the area of activity may be insufficient; rather, by means of the 
circulating fluids, it can be distributed to certain tissues that can determine the 
emergence of undesirable effects.  
 On other occasions, the active principle reaches an adequate concentration 
of its specific receptors, but this concentration is maintained for a short period of 
time. This forces the administration of the active principle to be repeated at short 
intervals of time, using conventional dosage methods for immediate release.  
 From a pharmaceutical point of view, the solution to these problems could 
lie in the chemical association of the active substance with an appropriate 
delivery preparation capable of specificity of action [64]. In this way, 
vectoring is defined as the attainment of maximum efficacy of a drug, by 
increasing its release in the area where its pharmaceutical receptors are found, 
thereby minimizing its concentration in other areas of the organism, reducing 
the adverse effects. So, one of the objectives of pharmaceutical research in 
recent decades has been the development of systems that release the active 
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principle selectively at the level of the damaged organ, without producing 
changes in healthy tissue. 
 Several advances to this effect have been made in the last 2-3 decades and 
novel drug delivery systems have been investigated.   
 Ability to solubilize and stabilize drugs, their high viscosity 
hydromiscibility, thermosensitivity and micellar behavior make the Pluronic 
gels a feasible vehicle for oral and topical control drug delivery. 
 Gels of pluronic as the vehicles for the percutaneous administration of 
anti-inflammatory [65], analgesic [66], peptides [67], beta-blockers [68] and 
other active principles were studied and evaluated. Additionally, in the early 
1990s Marty Jones and Lawson Kloesel [69] developed PLO (Pluronic Lecitin 
Organogel) as a transdermal drug carrier delivery system.  Recently, efficacy 
of transdermal use of different drugs has been demonstrated.   
 Organogels are semi-solid systems, in which an organic liquid phase is 
immobilized by a three-dimensional network composed of self-assembled, 
intertwined gelator fibers [70, 71]. The application of different organogel 
systems to transdermal via has been studied [72, 73]. 
 Microemulsions (clear, stable, isotropic mixtures of oil, water and 
surfactant in combination with a cosurfactant) are systems currently of interest 
to the pharmaceutical scientist because of their considerable potential to act as 
drug delivery transdermal vehicles (with diameters in the range of 20-100 nm)  
[74, 75]. However, it is necessary large amounts of surfactants to form 
microemulsions. Therefore, the use of these colloidal carrier systems in the 
future depends on the choice of well-tolerated surfactants and the restriction 
of their amounts. 
 Several excellent reviews discuss the advantages, limitations and 
opportunities offered by patches reservoir or matrix type in greater details and 
thus will not be covered in this review.  
 
4.2.1.2. Nanosystems or vesicles 
 
 Compared with other external skin preparations, such as creams and 
liniments, nanosystems provide more adjustable parameters in their 
preparation, and in treatments offer the advantages of enhancing drug effects, 
shortening the expected treatment course and lowering side effects. 
 Among the multiple advantages of these vectors, the following are shown: 
 
- Protects the active substance from deactivation (chemical, enzymatic or 
immunological), from the area of administration to the biophase. 
- Improves transport of the active principles to places difficult to reach. 
- Increases the specificity of action and efficacy at cellular and/or 
molecular level. 
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- Increases the average life span of the drug. 
- Modifies the soluble properties of the active substance and reduces its 
immunogenicity and antigenicity. 
- Decreases toxicity of certain organs by adjustment of the tissue 
distribution of the active principle. 
- Lacking in toxicity, they are biodegradable and can be prepared 
industrially on a large scale. 
 
 The most important factor for potential nanotoxicity is the lack of 
biodegradability of many nanomaterials. After generation of these 
nanomaterials, they will stay forever and pollute the environment and, 
considering the circle in the environment, finally end up in the human body. 
 In the other hand, lipid analysis of buccal tissues shows the presence of 
phospholipid 76.3%, glucosphingolipid 23.0% and ceramide NS at 0.72%. 
Other lipids such as acyl glucosylated ceramide, and ceramides [76]. In 
Stratum corneum, cellular membranes of keratinocytes are composed mainly 
of phosphatidyl choline and sphingomyelin. Also, the intercorneocyte matrix 
is rich in phospholipids.  
 In view of the above, in recent years a great importance has been attached 
to using lipids as vehicular systems and permeants of active principles through 
the skin and oral mucosa. The outstanding advantage of lipid vesicles is their 
easy and complete biodegradation. Lipids are natural materials, are easily 
degraded by natural processes such as enzymes. Phospholipids as drug carriers 
have some unique advantages which other conventional external preparations do 
not have. Phospholipids share a high structural similarity with skin lipids and 
thus have many advantages. They can moreover affect molecular transport 
across skin barrier more directly by acting as skin permeation enhancers. This 
type of application is particularly suitable for certain chronic and relapsing skin 
diseases, such as chronic eczema, psoriasis, neurodermitis, etc. 
 Several different kinds of lipid vesicles have been described in the 
literature. 
 Liposomes consist of amphiphilic molecules in a bilayer conformation. 
 In an excess of water these amphiphilic molecules can form one 
(unilamellar vesicles) or more (multilamellar vesicles) concentric bilayers 
[77]. Due to its structure, hydrophilic, amphiphilic and lipophilic drugs can be 
entrapped. 
 In recent years, most investigators have concentrated on the potential use 
of liposomes for the transdermal delivery of antibiotics [78], antiviral [79, 
anesthetics [80] and antiinflamatories [81]. 
 Niosomes are composed of non-ionic amphiphiles (surfactants) and are 
similar in function to the liposomes [82, 83]. 
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 Ethosomes are relatively new types of vesicle systems, primarily 
composed of water, ethanol and phospholipids [79]. 
 Sufficiently deformable and elastic vesicles can enter skin barrier 
spontaneously, e.g. transfersomes, which cross the skin under the influence of 
a transepidermal water activity gradient. Transfersomes consist of 
phospholipids and an edge activator that increases the deformability of the 
bilayers and is often a single chain surfactant. Recent studies show the 
effectiveness of elastic liposomes for transdermal delivery of melatonin [84]. 
 Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers 
(NLC), SLN are usually aqueous dispersions of solid lipid matrices stabilized 
by surfactants, or dry powders obtained by lyophilization [85] or spray drying 
[86], ranging from about 40 to 1000 nm. NCL are produced using blends of 
solid lipids and liquid lipids (oils) [87]. SLN and NLC exhibit many features 
for dermal application of cosmetics and pharmaceutics, i.e. controlled release 
of actives, drug targeting, occlusion and associated with it penetration 
enhancement and increase of skin hydration. Specifically, since the last 
decade, SLN have been exploited for delivery of actives via dermal [88-91]. 
They are an alternative carrier system to emulsions, liposomes and polymeric 
nanoparticles. Drugs for dermal application using lipid nanoparticles at the 
present are glucocorticoids, retinoids, non-steroidal anti-inflammatory drugs, 
COX-2 inhibitors, psoralens and antimycotics. It was shown that it is possible 
to enhance the percutaneous absorption with lipid nanoparticles. These 
carriers may even allow drug targeting to the skin or even to its substructures. 
Thus they might have the potential to improve the benefit/risk ratio of topical 
drug therapy [92]. 
 In the context it is noteworthy that physico-chemical characteristics of all 
these vesicles (size, charge, thermodynamic phase, lamellarity and bilayer 
elasticity) have a significant effect on the behaviour of the vesicles and hence 
on their effectiveness as a drug delivery system. Taking in account our aim 
they may serve as: 
 
- A local depot for the sustained release of dermal active compounds. 
- Penetration enhancer and facilitate dermal delivery leading to higher 
localized drug concentrations. 
- Rate-limiting membrane barrier for the modulation of systemic absorption 
or controlled transdermal delivery systems. 
 
4.2.2. Chemical enhancers 
 
 Generally the usual vehicles are not able to penetrate into stratum 
corneum by themselves. Penetration enhancement technology is a challenging 
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development that would increase the number of drugs available for 
transdermal administration. Thus for years different compounds capable of 
penetrating and transporting drugs have been studied, these are chemical 
substances temporarily diminishing the barrier of the skin and known as 
penetration promoters [93].  Promoters or accelerant can enhance drug flux, 
may act by one or more of three main mechanisms [94]: 
 
- Disruption of the highly ordered structure of stratum corneum lipid. 
- Interaction with intercellular protein.  
- Improved partition of the drug, coenhancer or solvent into the stratum 
corneum. 
  
 The selection of enhancer and its efficacy depends on the 
physicochemical properties of the drug, site of administration, nature of the 
vehicle and other excipients. These permeation enhancers should be safe and 
non-toxic, pharmacologically and chemically inert, non-irritant, and non-
allergenic. The different permeation enhancers available are: 
 
- Chelators: EDTA, citric acid, sodium salicylate, methoxy salicylates.  
- Surfactants: sodium lauryl sulphate, polyoxyethylene, Polyoxyethylene-9-
laurylether, Polyoxythylene-20-cetylether, Benzalkonium chloride, 23-
lauryl ether, cetylpyridinium chloride, cetyltrimethyl ammonium bromide. 
- Bile salts: sodium glycocholate, sodium deoxycholate, sodium 
taurocholate, sodium glycodeoxycholate, sodium taurodeoxycholate. 
- Fatty acids: oleic acid, capric acid, lauric acid, lauric acid/propylene 
glycol, methyloleate, lysophosphatidylcholine, phosphatidylcholine.  
- Non-surfactants: unsaturated cyclic ureas.  
- Hydrocarbons: alkanes, alkenes, halogenated alkanes, squalane, squalene 
and mineral oil. 
- Alcohols: alkanols, alkenols, glycols, polyglycols and glycerols. 
- Amines, amides, esters as isopropyl myristate.  
- Others: Terpenes, terpenoids, essential oils and phospholipids.  
- Thiolated polymers: chitosan-4-thiobutylamide, chitosan-4-
thiobutylamide/GSH, chitosan-cysteine, Poly (acrylicacid)-homocysteine, 
polycarbophil-cysteine, polycarbophil-cysteine/GSH, chitosan-4-
thioethylamide/GSH, chitosan-4-thioglycholic acid. 
 
 In general, it is challenging to strike an optimum balance between the 
safety and potency of chemical enhancers. In order to develop a transdermal 
penetration enhancer which a low irritation to the skin, alkyldisiloxanes 
containing sugar moiety with various alkyl chain length were investigated  
[95]. 
Advances in transdermal and transmucosa formulations 191 
 Nevertheless studies show that treatment with enhancers did not cause 
major morphological changes in the buccal tissue  [96]. 
 Based on such limitations, one can design synthetic enhancers [97] that 
are significantly more potent in their skin permeabilizing ability as compared 
to conventional chemicals as Azone (1-dodecylazacycloheptan-2-one).  
 Also, these limitations can be solved by synergistic effects between 
enhancers [98] and more polar co-solvents (e.g. ethanol, propylene glycol). 
Similarly, solvents such as Transcutol® are proposed to act by improving 
drug solubility within the membrane rather than by increasing drug diffusivity 
across it [99]. 
 
4.2.3. Physical enhancers: Devices 
 
 The ideal characteristics an active principle should have to penetrate the 
stratum corneum are: Aqueous solubility 1 mg mL-1, lipophilicity 10 Ko/w 
<1000, molecular weight <500 Da, melting point < 200 ºC, pH of saturated 
aqueous solution pH 5-9, dose deliverable 10 mg/day. 
 Unfortunately, drugs such as peptides, proteins and oligonucleotides are 
usually large, polar and/or charged, characteristics that normally preclude 
transdermal delivery. However, recent advances in physical enhancement 
technologies solve these problems. 
 These methods employed for increasing transport of drug molecules 
across the skin use some form of mechanical, electrical, magnetic or thermal 
energy source to promote transport of macromolecules by disrupting the skin 
membrane. With these new technologies the number of drugs potentially 
useful for transermal administration has greatly increased, and restrictions 
related to molecular weight, particle size, dosage, pH, etc. have been reduced.  
 Examples of physical approaches include the use of iontophoresis, 
electroporation, sonoporation, high velocity particles, ultrasound, electric 
current, abrasion, lasers, pressure waves, magnetophoresis and thermophoresis 
[100]. 
 Other modern methods for skin barrier breaching are micro-scale devices 
for transdermal macromolecular delivery: liquid jet injectors, powder 
injectors, microneedles, and thermal microablation [101].  
 Some of the obstacles in transdermal physical enhancers can be overcome 
by combining with other physical enhancement techniques for the delivery of 
macromolecules [102, 103]. 
 Similarly to transdermal, application studies on the mucosa physical 
enhancers improve the absorption of drugs, e.g. permeation of naltrexone on 
buccal mucosa was evaluated in presence of chemical enhancers or 
iontophoresis. No significant differences in penetration rate were observed 
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using chemical enhancers; in contrast, Js and Kp were extensively affected by 
application of electric fields [104]. 
 A particularly interesting perspective is the application of various 
physical methods used for gene delivery [105]. 
 Finally, note that some of these methods as iontophoresis, can be used as 
an in-vivo model for studying physiologic mechanisms and on the analysis 
and interpretation of dose–response data [106].  
 
5. Predicting transdermal and transbuccal delivery: In vitro - 
in vivo correlation 
 
 The main objective in the design and optimization of transdermal and 
transbuccal dosage forms lies in obtaining a good in vivo performance. Thus, 
one of the main challenges of biopharmaceutical research is finding a 
correlation between ex vivo, animal and human studies for prediction of 
percutaneous and transbuccal absorption in humans.  
 The permeability of oral mucosa and the efficacy of penetration enhancers 
have been investigated in numerous in vivo and in vitro models. Various types 
of diffusion cells, including continuous flow perfusion chambers, Franz cells 
and Grass-Sweetana cells, have been used to determine the permeability of 
oral mucosa [107]. Animal models generally are more available than human 
skin, but only rabbits and pigs have a non-keratinized mucosal lining similar 
to that in humans.   
 As for skin studies, several factors should be considered. The ideal model 
for in vitro permeation studies is the human skin. In this regard, skin from 
cadavers has approximately the same permeability as living skin, suggesting 
that the underlying tissues present little resistance to drug adsorption. 
 A wide range of animal models has been suggested as a suitable 
replacement for human skin and has been used to evaluate percutaneous 
permeation of molecules. However the most relevant animal model for human 
skin is the pig [108] and has less variability than the human skin model [109], 
also we can see that a synergistic mechanical and chemical on pig skin models 
exhibit similar permeabilities and pore radii, but the human skin models do 
not [110]. In fact, drug permeation through human skin at a selected skin site 
can vary from 46% to 66% among individuals [111]. Specifically, pig ear 
skin, which closely resembles human skin, is a candidate ex vivo alternative 
model for the investigation of xenobiotics penetration and metabolism. Also, 
due to its availability, skin of rodents (mice and rats) is commonly used in 
vitro and in vivo percutaneous permeation studies. 
Advances in transdermal and transmucosa formulations 193 
 On the other hand several studies with frozen or fresh skin have been 
made, highlighting the similarities between the two procedures. However, in 
general, the results demonstrate that the permeability of the drugs across the 
skin depends on the storage condition, the length of storage, vehicle and the 
physicochemical properties of the drug under study [112-114]. 
 To extrapolate the results obtained from experimentation with animal skin 
in vitro and in vivo to the human situation must be avoided unless scientific 
validation exists to show that this is appropriate for the given agent. 
 Cultured epithelial cell lines have also been developed as an in vitro 
model for studying drug transport and metabolism at biological barriers as 
well as to elucidate the possible mechanisms of action of penetration 
enhancers [115, 116]. However, the overall use of skin cultures is likely to be 
limited due to questionable performance as a barrier in skin permeation 
studies, as well as due to their cost and data reproducibility [117, 118]. 
 In order to assess the potential of transdermal therapy have been developed 
some pharmacokinetic models which are based on the physicochemical 
properties of the penetrant. Most models have focused on the contributions of 
molecular size and the solubility in stratum corneum lipids. These models 
provide kinetic equations which allow calculation of the plasma levels achieved 
after a drug is applied transdermally and transbuccally. A database of in vitro 
skin permeability coefficient values has been consolidated and over 20 
empirical equations have been published estimating permeability coefficients 
for chemicals penetrating the human skin from aqueous vehicles [119].  
 Plasma concentration time profiles for most of the transdermal and 
transbuccal systems are characterized in terms of AUC0–t (area under the 
time concentration curve from time 0 to time t), AUC 0–∞ (area under the 
time concentration curve from time 0 to infinity), Cmax (maximal plasma 
drug concentration) and Tmax (time to maximal plasma drug concentration). 
Cmax provides a practical estimate of Css (plasma concentration at steady 




 In many cases buccal and transdermal dose forms can obtain the same 
bioavailability as intravenous formulations without the disadvantages of this 
route of administration. 
 Despite the many advantages of the skin and oral mucosa as sites of drug 
delivery, only a few of drugs are currently in the market as transdermal 
delivery system (estradiol, ethinyl estradiol/levonorgestrol, ethinyl 
estradiol/norelgestromin, ethinyl estradiol/norethindrone, clonidine, 
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oxybutinin, fentanyl, methylphenidate, nicotine, nitroglycerin, selegiline, 
scopolamine, testosterone, rivastigmine and rotigotine). 
 Because the stratum corneum limits the amount of drug reaching the 
blood supply and unless the barrier function is reduced with a penetration 
enhancer it is unlikely that plasma levels above 100 ng/mL will be           
attained.  
 This paper explains why and how skin or oral mucosa preclude essentially 
any large molecules transport into body, the achievements of transdermal and 
transmucosal scientists and the new technologies for enhancement the dosage 
forms across these routes. In this way several physical, chemical and 
nanosystems methods have been investigated, which can only enhance the 
drug disposal in the skin and others however, could lead to therapeutic drug 
concentrations in the systemic circulation.   
 To face the design of these and others excipients, “in vitro” release studies 
will constitute an essential tool for its development. It also will let us know 
the dermal penetration values of drugs and the effectiveness of vehicles.  
  Therefore, in order to assess the potential of transdermal or transbuccal 
therapy, it is necessary the development of more experiences and new release 
vehicles for transdermal and transbuccal drugs. 
 Lastly it should be noted that other routes, such as nasal, ocular, 
pulmonary, rectal, and vaginal drug administration, have provided excellent 
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